UNSPSC 51311801: Astemizole

This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H31FN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7HU6337315, chemically known as 1h-benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-n-(1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)- but generally known as astemizole, which bears US NIH Compound Identifier 2247. European Medicines Agency schedules Astemizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05586MIG.

UNSPSC 51311801 Astemizole is a Commodity code that in recent state and local solicitations has been applied broadly to pharmaceutical procurement across multiple product categories and delivery channels, though the code's nominal scope does not align cleanly with the opportunities posted under it. State and local governments are buying pharmaceuticals and drug-related products through this taxonomy—including naloxone and drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—but the recent opportunities show little activity specifically for astemizole, an antihistamine medication. Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration's Office of State Procurement (through the MMCAP cooperative) have posted opportunities in this space, indicating that state agencies and regional cooperatives are the primary buyers rather than individual municipalities or school districts.

Recent activity spans Florida, Texas, and Minnesota. The most concrete opportunity is Seminole County's IFB 60459723LAS (posted June 30, 2026, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and an initial two-year contract term with one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, designed as a market-intelligence phase preceding formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards, with evaluation weighted 75 percent on price competitiveness.